{"ticker": {"uuid": "b900d6f5-bdf3-4a85-8519-c09cce792794", "symbol": "KYMR", "name": "Kymera Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140", "summary": "Piper Sandler has reiterated its Buy rating for Kymera Therapeutics (KYMR.US), maintaining a target price of $140. This continued endorsement suggests confidence in the company's future performance.", "url": "https://www.moomoo.com/news/post/73077892/piper-sandler-maintains-kymera-therapeutics-kymrus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-16T20:09:52", "published_display": "16 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)", "summary": "Purcell & Lefkowitz LLP has initiated a shareholder investigation into Kymera Therapeutics, Inc. (NASDAQ: KYMR) to determine if its directors breached their fiduciary duties regarding recent corporate actions. Shareholders of Kymera Therapeutics are encouraged to contact the law ", "url": "https://www.prnewswire.com/news-releases/shareholder-alert-purcell--lefkowitz-llp-announces-shareholder-investigation-of-kymera-therapeutics-inc-nasdaq-kymr-302827613.html", "source_name": "PR Newswire", "published_at": "2026-07-16T15:41:41", "published_display": "16 Jul 2026 15:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYMR Maintained by Mizuho -- Price Target Raised to $140", "summary": "Mizuho has maintained an \"Outperform\" rating for Kymera Therapeutics (KYMR) and increased its price target from $120 to $140, reflecting confidence in the company's potential. Despite this positive outlook, GuruFocus indicates that KYMR is significantly overvalued at 385.4% above", "url": "https://www.gurufocus.com/news/8962324/kymr-maintained-by-mizuho-price-target-raised-to-140", "source_name": "GuruFocus", "published_at": "2026-07-16T12:41:41", "published_display": "16 Jul 2026 12:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Raises Price Target on Kymera Therapeutics to $140 From $120, Keeps Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mizuho-raises-price-target-kymera-110246168.html", "source_name": "MT Newswires", "published_at": "2026-07-16T11:02:46+00:00", "published_display": "16 Jul 2026 11:02", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) AGM 2024 Summary", "summary": "This article summarizes Kymera Therapeutics' (KYMR) 2024 Annual General Meeting, highlighting the agenda, board and executive updates, and four shareholder proposals discussed. It also provides a quick overview of recent company events and clinical advancements, including progres", "url": "https://quartr.com/events/kymera-therapeutics-kymr-agm-2024_onc93imc", "source_name": "Quartr", "published_at": "2026-07-16T10:41:41", "published_display": "16 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) 44th Annual J.P. Morgan Healthcare Conference Summary", "summary": "Kymera Therapeutics (KYMR) presented its strategic vision and pipeline progress at the 44th Annual J.P. Morgan Healthcare Conference. The company is focused on developing novel oral drugs for immune-inflammatory diseases, aiming to expand access for 160 million patients and revol", "url": "https://quartr.com/events/kymera-therapeutics-inc-kymr-44th-annual-j-p-morgan-healthcare-conference_onc9eaKJ", "source_name": "Quartr", "published_at": "2026-07-16T09:43:06", "published_display": "16 Jul 2026 09:43", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) Jefferies London Healthcare Conference 2025 Summary", "summary": "Kymera Therapeutics (KYMR) presented a summary of its strategic focus and pipeline at the Jefferies London Healthcare Conference 2025. The company is developing oral medicines using targeted protein degradation, primarily in immunology, with a strong focus on its STAT6 program fo", "url": "https://quartr.com/events/kymera-therapeutics-inc-kymr-jefferies-london-healthcare-conference-2025_onc9etYa", "source_name": "Quartr", "published_at": "2026-07-16T09:41:41", "published_display": "16 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Kymera Therapeutics For: 13 July By Investing.com", "summary": "This article from Investing.com reports on a Form 144 filing by Kymera Therapeutics, dated July 13. Form 144 is a notice of the intent to sell restricted securities without registration. The article itself is very brief, mainly serving as a headline for the filing.", "url": "https://ng.investing.com/news/stock-market-news/form-144-kymera-therapeutics-for-13-july-93CH-2597717", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T23:08:00", "published_display": "13 Jul 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Markets has adjusted its investment rating for Kymera Therapeutics Inc., downgrading it from \"outperform\" to \"sector perform.\"", "summary": "RBC Capital Markets has downgraded its investment rating for Kymera Therapeutics Inc. from \"outperform\" to \"sector perform.\" Despite the downgrade, the institution increased its target share price for Kymera from $106 to $115. The article includes a disclaimer stating that the co", "url": "https://www.bitget.com/amp/news/detail/12560605502380", "source_name": "Bitget", "published_at": "2026-07-13T20:10:40", "published_display": "13 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics Shares Fall After RBC Downgrade", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/kymera-therapeutics-shares-fall-rbc-190927480.html", "source_name": "MT Newswires", "published_at": "2026-07-13T19:09:27+00:00", "published_display": "13 Jul 2026 19:09", "sentiment": "negative", "sentiment_pct": 22, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "RBC Downgrades Kymera Therapeutics to Sector Perform From Outperform, Lifts Price Target to $115 From $106, Keeps Speculative Risk", "summary": "RBC has downgraded Kymera Therapeutics (KYMR) from Outperform to Sector Perform. Despite the downgrade, the firm increased its price target for Kymera Therapeutics to $115 from the previous $106, while maintaining a speculative risk assessment for the stock. This adjustment refle", "url": "https://www.marketscreener.com/news/rbc-downgrades-kymera-therapeutics-to-sector-perform-from-outperform-lifts-price-target-to-115-fro-ce7f5edfd18efe23", "source_name": "marketscreener.com", "published_at": "2026-07-13T10:43:00", "published_display": "13 Jul 2026 10:43", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera's CEO Sold $6 Million in Stock After a 170% Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPcFFWRmc3OVBwQ2w5ZDZydDBOeEtaUXBuZFd0MzFTYlR6TWs5eURvMEhuOS1qWWJrNjl1LUJzUktSc3JxV0cxNHE4WUo1ZkF5NTd3X2NnNHZhTTBvOHNsQzhJUlRjWVphLXRlYkx3OHhhNVdjLW9IRzdWSU01ME5JdzdlVWpGOWd4V3BOb1gxVjZIOElaMVE?oc=5", "source_name": "Market source", "published_at": "2026-07-12T20:57:46+00:00", "published_display": "12 Jul 2026 20:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Leadership Hire And Benchmark Additions Change The Bull Case For Kymera Therapeutics (KYMR)?", "summary": "Kymera Therapeutics has appointed Elizabeth Laws as SVP and KT-621 Development Program Leader and been added to Russell value and small-cap benchmarks, which are significant operational and market-profile milestones. These developments, particularly Laws' experience with immunolo", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/does-leadership-hire-and-benchmark-additions-change-the-bull", "source_name": "Simply Wall Street", "published_at": "2026-07-10T16:46:38", "published_display": "10 Jul 2026 16:46", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Kymera (KYMR) the Best Performing American Stock in June 2026?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/kymera-kymr-best-performing-american-104037406.html", "source_name": "Insider Monkey", "published_at": "2026-07-09T10:40:37+00:00", "published_display": "09 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics CEO Mainolfi sells $5.95m in stock", "summary": "Nello Mainolfi, CEO of Kymera Therapeutics, sold $5.95 million worth of company stock after exercising options. The transaction involved 50,000 shares at $119.00 each, occurring when KYMR shares were near their 52-week high after a significant 175% return. This comes as the compa", "url": "https://www.investing.com/news/insider-trading-news/kymera-therapeutics-ceo-mainolfi-sells-595m-in-stock-93CH-4780593", "source_name": "Investing.com", "published_at": "2026-07-08T17:42:18", "published_display": "08 Jul 2026 17:42", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics(KYMR.US) Officer Sells US$5.95 Million in Common Stock", "summary": "A Kymera Therapeutics (KYMR.US) officer sold a significant amount of common stock, totaling US$5.95 million. This transaction indicates insider selling activity at the company.", "url": "https://www.moomoo.com/news/post/72609560/kymera-therapeutics-kymrus-officer-sells-us-5-95-million-in", "source_name": "Moomoo", "published_at": "2026-07-08T17:42:18", "published_display": "08 Jul 2026 17:42", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics Insider Sold Shares Worth $5,950,000, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/kymera-therapeutics-insider-sold-shares-073158288.html", "source_name": "MT Newswires", "published_at": "2026-07-08T07:31:58+00:00", "published_display": "08 Jul 2026 07:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Kymera Therapeutics Inc For: 7 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Kymera Therapeutics Inc, dated July 7th. It indicates a stock performance of -3.10% for KYMR. The article primarily serves as a placeholder for the Form 4 information, surrounded by general market data and news headli", "url": "https://ng.investing.com/news/stock-market-news/form-4-kymera-therapeutics-inc-for-7-july-93CH-2590124", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T00:39:36", "published_display": "08 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics CEO Mainolfi sells $5.95m in stock By Investing.com", "summary": "Kymera Therapeutics, Inc. CEO Nello Mainolfi sold 50,000 shares of common stock worth $5.95 million after exercising stock options. This transaction was executed under a Rule 10b5-1 trading plan. The sale followed significant company advancements, including accelerated enrollment", "url": "https://m.za.investing.com/news/stock-market-news/kymera-therapeutics-ceo-mainolfi-sells-595m-in-stock-93CH-4359585?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-08T00:10:48", "published_display": "08 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) Following Faster KT 621 Trial Progress Still Looks Modestly Undervalued", "summary": "Kymera Therapeutics (KYMR) has completed patient enrollment for its KT-621 trial ahead of schedule, accelerating the timeline for topline data. Despite recent strong share price performance and index inclusion, analysts suggest the stock is still modestly undervalued, with a cons", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/kymera-therapeutics-kymr-following-faster-kt-621-trial-progr", "source_name": "Simply Wall Street", "published_at": "2026-07-07T11:10:48", "published_display": "07 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader", "summary": "Kymera Therapeutics has appointed Elizabeth Laws, Ph.D., as Senior Vice President, KT-621 Development Program Leader. Dr. Laws, formerly an immunology leader at Sanofi, will lead the global development strategy for KT-621, a first-in-class oral STAT6 degrader for immunological di", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/GlobeNewswire/3158526/kymera-therapeutics-appoints-elizabeth-laws-ph-d-as-senior-vice-president-global-program-team-leader-for-kt-621-first-in-class-oral-stat6-degrader/", "source_name": "The Globe and Mail", "published_at": "2026-07-07T11:10:47", "published_display": "07 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics Insider Sold Shares Worth $8,864,829, According to a Recent SEC Filing", "summary": "A recent SEC filing revealed that an insider at Kymera Therapeutics sold shares valued at $8,864,829. This transaction provides insight into insider activity at the company.", "url": "https://www.moomoo.com/news/post/72506052/kymera-therapeutics-insider-sold-shares-worth-8864829-according-to-a?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T05:10:48", "published_display": "07 Jul 2026 05:10", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics Insider Sold Shares Worth $9,223,527, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/kymera-therapeutics-insider-sold-shares-081145747.html", "source_name": "MT Newswires", "published_at": "2026-07-06T08:11:45+00:00", "published_display": "06 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYMR - Kymera Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of Kymera Therapeutics Inc (KYMR), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider/institutional o", "url": "https://finviz.com/stock?t=KYMR&ta=1&p=d&ty=oc&r=m3&ov=list_strike&s=55", "source_name": "Finviz", "published_at": "2026-07-04T16:10:19", "published_display": "04 Jul 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYMR - Kymera Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial snapshot of Kymera Therapeutics Inc (KYMR), listing key metrics such as market capitalization, sales, earnings per share, and various financial ratios. It also includes information on volatility, share performance over different periods,", "url": "https://finviz.com/stock?t=KYMR&ta=1&p=d&ty=ocv&b=2&e=2026-07-17", "source_name": "Finviz", "published_at": "2026-07-03T13:39:11", "published_display": "03 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) Is Up 16.7% After KT-621 Trial Acceleration And Index Additions Has The Bull Case Changed?", "summary": "Kymera Therapeutics (KYMR) has seen a 16.7% stock increase following the early completion of enrollment for its KT-621 Phase 2b trial, updated timelines for data and Phase 3 initiation, new Board Chairman Felix J. Baker, and inclusion in Russell indices. These developments accele", "url": "https://www.sahmcapital.com/news/content/kymera-therapeutics-kymr-is-up-167-after-kt-621-trial-acceleration-and-index-additions-has-the-bull-case-changed-2026-07-01", "source_name": "Sahm", "published_at": "2026-07-03T04:40:36", "published_display": "03 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) Stock Looks Fully Priced After A 405% Run", "summary": "Kymera Therapeutics (KYMR) stock has seen a 405% return over three years but appears expensive based on Simply Wall St\u2019s valuation checks, scoring 1 out of 6. The article questions whether the recent surge and high valuation leave enough room for investors, given the remaining ri", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/kymera-therapeutics-kymr-stock-looks-fully-priced-after-a-40", "source_name": "Simply Wall Street", "published_at": "2026-07-03T04:10:30", "published_display": "03 Jul 2026 04:10", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics(KYMR.US) Officer Sells US$9.22 Million in Common Stock", "summary": "A Kymera Therapeutics (KYMR.US) officer recently sold common stock valued at $9.22 million. This significant insider transaction could be noted by investors monitoring company leadership's actions.", "url": "https://www.moomoo.com/news/post/72420282/kymera-therapeutics-kymrus-officer-sells-us-9-22-million-in", "source_name": "Moomoo", "published_at": "2026-07-03T01:10:30", "published_display": "03 Jul 2026 01:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Noah Goodman Sells Shares of Kymera Therapeutics Inc (KYMR)", "summary": "Noah Goodman, Chief Business Officer at Kymera Therapeutics Inc, sold 3,389 shares of the company on July 1, 2026. This sale follows a pattern of 45 insider sells against only 1 insider buy over the past year. The stock is currently trading at $114.29, which is significantly over", "url": "https://www.gurufocus.com/news/8943940/insider-sell-noah-goodman-sells-shares-of-kymera-therapeutics-inc-kymr", "source_name": "GuruFocus", "published_at": "2026-07-03T00:09:38", "published_display": "03 Jul 2026 00:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(SEC Amendment) Kymera Therapeutics(KYMR.US) Director Sells US$8.28 Million in Common Stock", "summary": "A director at Kymera Therapeutics (KYMR.US) sold common stock valued at US$8.28 million. This information was disclosed in an SEC Amendment filing.", "url": "https://www.moomoo.com/news/post/72419479/sec-amendment-kymera-therapeutics-kymrus-director-sells-us-8-28", "source_name": "Moomoo", "published_at": "2026-07-02T22:09:39", "published_display": "02 Jul 2026 22:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug", "summary": "Kymera Therapeutics (KYMR) stock has risen 50.9% year-to-date due to strong investor optimism surrounding its lead drug candidate, KT-621, for atopic dermatitis and asthma. The company recently completed enrollment for its phase IIb BROADEN2 study ahead of schedule, with pivotal ", "url": "https://finance.yahoo.com/healthcare/articles/kymr-stock-soars-51-ytd-170600007.html", "source_name": "Market source", "published_at": "2026-07-02T15:40:02", "published_display": "02 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Kymera Therapeutics For: 2 July By Investing.com", "summary": "This article announces the filing of Form 144 for Kymera Therapeutics (KYMR) on July 2nd, without providing further details on the content of the filing. It is presented within a news aggregator format by Investing.com, surrounded by various market data and other news headlines. ", "url": "https://ca.investing.com/news/stock-market-news/form-144-kymera-therapeutics-for-2-july-93CH-4718312", "source_name": "Investing.com Canada", "published_at": "2026-07-02T12:40:52", "published_display": "02 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) Stock Gets Fair Value Bump After KT 621 Timeline Shift", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPV1hWRnp3bkY1ZEhreGhYSWFBR2FVcHlNY3RCRFUyR1RlNXR0UVZSNW5OcWxKblYtUjQ5YndhZ2tuZmxqaXBidFN4WmtyaF94NTVZQWVSSS1WLWFvTTJsc0c2a2VvWXRuMWFkNnRsS0N4aWZaeEFCSFlVc3hFQlRJRkNfZ0c3LU92ZGJlQ0E1RW9DU0tvVWQ5Sm1rUl9HZk14YVE?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Accelerated KT-621 Trial, Index Additions, and New Chair Will Impact Kymera Therapeutics (KYMR) Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNdGlDbk9uOTBvZ3hMaWxjSzBSVEpIZFkwSWMteThJbGkwVmtGbWdfOW1XVE9samc4NG1nYVVYNkd2NFN0OVNLYkdoNDhQa00tUEdIWlljZmJBaFowYTNvaUFQdy1URDZBNnpLR1p3VVZYLVlGaUE3MzFjMkVRWEZIN3pLRW1FdGxZam9JaWdxRTBsQnFkT3c?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics(KYMR.US) Director Sells US$59.88 Million in Common Stock", "summary": "A director at Kymera Therapeutics (KYMR.US) has recently sold common stock valued at US$59.88 million. This significant insider transaction indicates a major change in the director's holdings in the company. Further details regarding the transaction would be available in the offi", "url": "https://www.moomoo.com/news/post/72287802/kymera-therapeutics-kymrus-director-sells-us-59-88-million-in", "source_name": "Moomoo", "published_at": "2026-07-01T14:40:52", "published_display": "01 Jul 2026 14:40", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Kymera Therapeutics Inc For: 30 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNWEF4eE5NbDFSc3hCcTFlOEoxQk05bjhNVWxqdmpTSVByQzR3ZmgwcGNDTlVFVmdxR1M0YTNVUkV4eWlBT1lrNXRQR254bnpBNURXa2liRldEVUJSeXdRZlpCTXBxUGE3V25sSngtQ0t4cGp2UmFuNEVxNjU5QkJkX2NucFFkS3hLOEZ2MmFVcTRNZnNxTV9FbkRNTzk3MkVDWnBSdmZB?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-30T21:40:21+00:00", "published_display": "30 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 | Kymera Therapeutics(KYMR.US) Insider Proposes to Sell 6.69 Million in Common Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPdGdKN1ZLcHZDSlFZd2xoSTFhdTlmRW5iT3owVmIyUi1lWEcyX3RfaWNVa3M0dGFJNWowYW13cWttdkduS0lsejl4Mlo3eEFZaXFLc25ERWR6ZjB3cHNPR3QwTDVXT0JOVEZVLWFjWUlYWUJ0eVhSQ1lDaVI3emNrMHJiV3R4a1RaSU1SSVp4S09YVWVVTXY1ZzUwNHlZYXVrVjRBZHowUXA?oc=5", "source_name": "Moomoo", "published_at": "2026-06-26T20:52:32+00:00", "published_display": "26 Jun 2026 20:52", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Kymera Therapeutics Inc For: 26 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOUFBsR0RqdkNYUVFnSldmeERObVBvbHJOdG0xTTdGNHZKa0JkdFZyUmJWS1VMVzRoeHVyaHBTRGJUOFV2SUZVanRNTVU5aEw0RTl5VTJSNU1ZWUhxV09pNm9RNmJWTkNlUjdTaE0xWjQ1WGdRVmZYWUgxeXcwaFJ0bW9WMzlsdmpDeW9XbEVZSVdXVEZhTmFsUDBwSVRDVENUTEEzX1V3?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Kymera Therapeutics Stock Popped This Week", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOZ0xrTVd0cFRpY2NpR3F6dnNXb05USlFYUk5lS3JRNGFZN2pnMC1mMWtQaFAwYjF0elYyQWNLUFh0NGN4YmZ6Zy1TSzBZVjJmSGpaRGN1YlBPb3lEZnVZVEM4NXc2QUlOUE9NOHdEdnpCdVJrcm5TMkNtaktsRnlEYU4tbGZQS2tSQTJsUS1OSENaWGM?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPNVJSUFYwNjhObF9wMVE4dzBrWHZDWnVGUGI5WDJxMC0zZVl2NU1uYy1PUE1XVDhMb3d5dmJWS1lVVnVIU3E4eWNfWjdjRkUtNHpMMGg2a09XVEs3Z0tVVzVDckR3SjVaTlgzUXNlMUhqQUp2VExyOFdQd3RvZURFNTFKZlFNM3kwRjJEUjJWUUdCU0VNTGZmWTZncWhHaVRfODNvTWRR?oc=5", "source_name": "Market source", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics KYMR Stock Surges On Sanofi Milestone", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOSXBZb1VVUmNDWGxYTnUzdlBJek10Q2ZPdGc0MjRoVUV5Vkg0Tm9YQjJ3YXozNjlVYVo4OEN6RkhJdnYtZUJWV0lfZVNBUHRYYmptdlhTMEtGNHB4TFJsakpYbEVGVW4zb1ZVbVlSM25iNlpsZVpxemcxVkVxaHNSQm5jVQ?oc=5", "source_name": "timothysykes.com", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics KYMR Jumps As Degrader Pipeline Advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOR1F0eFh6S2FfSHZjNDRsVm9UM2VvM2l3N0Y5XzhXTDNCa3NIdVJrQ0F3VVFkYTBQdWlDMktsQUI4UExhVlllYXVDYU80Q05TcjUyNTJGNXhVVXE5QmNUakJDTHJjbGlnNkVTbE1Ec3lnMUpaUEN3ZHNMbnY3bWlxZXJsaTQ?oc=5", "source_name": "StocksToTrade", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics KYMR Stock Jumps On Pipeline Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOUXdZcWdwQmxIanJNZUhUTXAyMkpRdXNlbXdsdHFJdk90SDJMdlNYUFNzdTE0dUNKdkZLNl83VnJoN2swWFRmNS01dXg0Rk5PTmZhbnNYeEFsSkdtZ09ZMDBTSTJaT0NUelNrRkdNN2REWl85MEozRUNRNXJhZXlJdkZnQmNNQlBU?oc=5", "source_name": "timothysykes.com", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) Soars As Pipeline And Partnerships Advance", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPYk5Db290ZWwzb3NhdkR6ZTliUUxCZjd2bWlPX1ZhSzNLRWNyU1hBQ1ZvajNvai1WMXBjdWJkRWRxaHRRemxKbEpiX1UyQmJrRnhIY1k5VlE4LV9xMU9IUktaM1ZYWUFPbHlsS0wwN1V1aTZ3a0V6ZjZxdVFoSHNKcQ?oc=5", "source_name": "timothysykes.com", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera stock climbs on expedited eczema study (KYMR:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPUVZrV2MwZXIzbVBSbHFTTHh5MnQwY2JRRVYwY2YwTkZUUGxlNWF2NkZsMlBmS3lPS3lGOThRWWpjYlZFdENPNEJpOF9IYklISjhFR09uWC1aa2xpSUZ5OXBwdk1mWkZUMzVPeHNEcXRvOHdfM085T3pleFU1UEdIOHJCS1paaWM?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOZEZCS1ppUktfdFdFb1JQWDYxdkcwcnU4TTBFY1lYbklPWmlSNFpzRUxLaExGZW51OGhmRTgzcElFTW9iRWg3UFRkZ0dhVTI1S0JVWkpZbjdsOEtNbjhPNmdRLVJUSlNteFd5a040M2F5ZTVlUUthTFAtcUNfRnhEeDNxVENYN29FM2xZUDBxNmdpWXJqWHZJVklYZEFkVWc?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Kymera Therapeutics Inc For: 22 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPckZlVTExeDFRamY2MU9EMXR2Q0RNbGl2YWcwYWtYeVVmUGctSTg3akVlUzdkSXZ1a0pjdU1OZy0xXzVmaVkwYW9JZnhROTNnQUFkeUF2VVNmWkJKakRzcDdMTVN5aGY5dlZLWGhjZWZxaUJCaGthaU9hV3hDeDF5a1pFUlRlMEgyajlob05vQmtMUTNxN0d2TVJ1UFlRSlg5UEY1VXFB?oc=5", "source_name": "Investing.com India", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics Stock (KYMR) Opinions on Director's Substantial Share Sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNekJmTm5SYm1adHUxaTdreTNtY3Z1NmlwLXRabkVWXzZQOTE5VXdBOVlUNzY4TWVNVmhqcHpiOUR3bDlua0RXSW5Cc2hVTXgtNkVHVjNvbXRCeWg0UEwwT25vaXlFeFV2cEN5UUZ5R3RJTlMtVGRFdy1uVEJSNHV1MW1CTVhHbjF0dDNVTnl6RGFUUFhlTmdlWjJLUUJjSi1TcjRHUVpsMWpndWxTZGxEczk3OVdJUkl5?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Kymera Therapeutics stock surging today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxONkxIT2M4R0ROd29BT2doLVk1dTFHT3doX2VRNm01NzR6WUJHYzYxRm1GRVEyT21EYnhIV2poTkViQ196ZHhXckV1VS1uT1IyemtVeWdQWjJUTFJCZGdYV1l6LVNxcVYxMVpybmlLZXZBR3lTdDhvV2g3MDZzZF85eTJqTC1XUTlzYTdQTDZud1BPa0R5RjRod0R6RnFNc2FwdXpWOHVLemYwMWlL?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Kymera Therapeutics (KYMR) Valuation After Recent Share Price Rebound", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPZHJ1NjlCSDVfdl9vTGp0b2xoTGVXY19CcmVHNDRkd3JTdU1hYnpqSGhwSHF6N0Q4MFhETVA3QnpETWp4VW1YTnRCRThabi0tM0NqS3BYSm8wVzFfR1VZbHdJZVBTQUZhaXJjQkViYkRzcnI4S1VEczd0dU16aEZmNEVDS1VrSllsR25tR2FHN1VxdW80VHFRb2EwRmxTQTRRUnJKLTA0dXpYT291eEE?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Kymera Therapeutics (KYMR) Investment Narrative Is Evolving Without New Analyst Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQR3hzVTZWLXhRYy1vcWJZanYzVFJSMmN2VW5fRTV4QTBqSXc5clFvWU9aekpmNGMtajRFXzBISXVGZWpodE95a2FEQWk2cERlZDIySE9ubktFMTRoZjN1VVNLSkZmRHg4a21VanVxYmlBR1MwQVdZQjhjVnBYQlQ5X0tYWmNpMGdxeG5jZzUtX0JoRFFnOGlPUTlsdW1UdF9udkVpeXVITVZsc3FXT1RJ?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) Valuation Check After New KT-621 And KT-579 Clinical And Preclinical Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPNEJ1UmZDT2R1X0JMTk54cVFJN1o0Zml5SmFDN1FVUkw5eEtJeXkwdklmQmNBS0thV3VRV1RrMmp4RnVrYkRSZGdUZVNWM0VUVW5hUHl6M01oUG03WUxmSkJ4eW9ESlRVVEg5U3hCN2xaTWx6a0xqaURxZHZRWGV6d0pVOHktMjBKOFdiR0ZIcGdLSVhLbWdQVWVNdzdnSGdKRTdYemJVMDBPLTBvNHc?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How The Kymera Therapeutics (KYMR) Story Is Shifting Around KT-621 And Degrader Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPZDdVRmJ3T1YtcV9lZTFZSnFlYUI5VUxFbXhBSVNOOHJuMTJocHNacldhZllRZzJQa3dTUldHSnlRYkpVSkh6NWJfa2dqOVNVaVQ3WmU4b1JGSVBId3MwMlJ0Rk1FSk5KYkJCYmdUZFZGSm1YMllYS2prS2RmdDlSWnM5MjR5SHhuOHJIWWJKdnI1NVZUYXM1bksxOWp5MHJmcWUtVk93S29jcTdL?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) Q1 2026 Deepening Losses Test Bullish Revenue Growth Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140", "summary": "Piper Sandler has reiterated its Buy rating for Kymera Therapeutics (KYMR.US), maintaining a target price of $140. This continued endorsement suggests confidence in the company's future performance.", "url": "https://www.moomoo.com/news/post/73077892/piper-sandler-maintains-kymera-therapeutics-kymrus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-16T20:09:52", "published_display": "16 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)", "summary": "Purcell & Lefkowitz LLP has initiated a shareholder investigation into Kymera Therapeutics, Inc. (NASDAQ: KYMR) to determine if its directors breached their fiduciary duties regarding recent corporate actions. Shareholders of Kymera Therapeutics are encouraged to contact the law ", "url": "https://www.prnewswire.com/news-releases/shareholder-alert-purcell--lefkowitz-llp-announces-shareholder-investigation-of-kymera-therapeutics-inc-nasdaq-kymr-302827613.html", "source_name": "PR Newswire", "published_at": "2026-07-16T15:41:41", "published_display": "16 Jul 2026 15:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYMR Maintained by Mizuho -- Price Target Raised to $140", "summary": "Mizuho has maintained an \"Outperform\" rating for Kymera Therapeutics (KYMR) and increased its price target from $120 to $140, reflecting confidence in the company's potential. Despite this positive outlook, GuruFocus indicates that KYMR is significantly overvalued at 385.4% above", "url": "https://www.gurufocus.com/news/8962324/kymr-maintained-by-mizuho-price-target-raised-to-140", "source_name": "GuruFocus", "published_at": "2026-07-16T12:41:41", "published_display": "16 Jul 2026 12:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Raises Price Target on Kymera Therapeutics to $140 From $120, Keeps Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mizuho-raises-price-target-kymera-110246168.html", "source_name": "MT Newswires", "published_at": "2026-07-16T11:02:46+00:00", "published_display": "16 Jul 2026 11:02", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) AGM 2024 Summary", "summary": "This article summarizes Kymera Therapeutics' (KYMR) 2024 Annual General Meeting, highlighting the agenda, board and executive updates, and four shareholder proposals discussed. It also provides a quick overview of recent company events and clinical advancements, including progres", "url": "https://quartr.com/events/kymera-therapeutics-kymr-agm-2024_onc93imc", "source_name": "Quartr", "published_at": "2026-07-16T10:41:41", "published_display": "16 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) 44th Annual J.P. Morgan Healthcare Conference Summary", "summary": "Kymera Therapeutics (KYMR) presented its strategic vision and pipeline progress at the 44th Annual J.P. Morgan Healthcare Conference. The company is focused on developing novel oral drugs for immune-inflammatory diseases, aiming to expand access for 160 million patients and revol", "url": "https://quartr.com/events/kymera-therapeutics-inc-kymr-44th-annual-j-p-morgan-healthcare-conference_onc9eaKJ", "source_name": "Quartr", "published_at": "2026-07-16T09:43:06", "published_display": "16 Jul 2026 09:43", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) Jefferies London Healthcare Conference 2025 Summary", "summary": "Kymera Therapeutics (KYMR) presented a summary of its strategic focus and pipeline at the Jefferies London Healthcare Conference 2025. The company is developing oral medicines using targeted protein degradation, primarily in immunology, with a strong focus on its STAT6 program fo", "url": "https://quartr.com/events/kymera-therapeutics-inc-kymr-jefferies-london-healthcare-conference-2025_onc9etYa", "source_name": "Quartr", "published_at": "2026-07-16T09:41:41", "published_display": "16 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Kymera Therapeutics For: 13 July By Investing.com", "summary": "This article from Investing.com reports on a Form 144 filing by Kymera Therapeutics, dated July 13. Form 144 is a notice of the intent to sell restricted securities without registration. The article itself is very brief, mainly serving as a headline for the filing.", "url": "https://ng.investing.com/news/stock-market-news/form-144-kymera-therapeutics-for-13-july-93CH-2597717", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T23:08:00", "published_display": "13 Jul 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Markets has adjusted its investment rating for Kymera Therapeutics Inc., downgrading it from \"outperform\" to \"sector perform.\"", "summary": "RBC Capital Markets has downgraded its investment rating for Kymera Therapeutics Inc. from \"outperform\" to \"sector perform.\" Despite the downgrade, the institution increased its target share price for Kymera from $106 to $115. The article includes a disclaimer stating that the co", "url": "https://www.bitget.com/amp/news/detail/12560605502380", "source_name": "Bitget", "published_at": "2026-07-13T20:10:40", "published_display": "13 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics Shares Fall After RBC Downgrade", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/kymera-therapeutics-shares-fall-rbc-190927480.html", "source_name": "MT Newswires", "published_at": "2026-07-13T19:09:27+00:00", "published_display": "13 Jul 2026 19:09", "sentiment": "negative", "sentiment_pct": 22, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Downgrades Kymera Therapeutics to Sector Perform From Outperform, Lifts Price Target to $115 From $106, Keeps Speculative Risk", "summary": "RBC has downgraded Kymera Therapeutics (KYMR) from Outperform to Sector Perform. Despite the downgrade, the firm increased its price target for Kymera Therapeutics to $115 from the previous $106, while maintaining a speculative risk assessment for the stock. This adjustment refle", "url": "https://www.marketscreener.com/news/rbc-downgrades-kymera-therapeutics-to-sector-perform-from-outperform-lifts-price-target-to-115-fro-ce7f5edfd18efe23", "source_name": "marketscreener.com", "published_at": "2026-07-13T10:43:00", "published_display": "13 Jul 2026 10:43", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera's CEO Sold $6 Million in Stock After a 170% Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPcFFWRmc3OVBwQ2w5ZDZydDBOeEtaUXBuZFd0MzFTYlR6TWs5eURvMEhuOS1qWWJrNjl1LUJzUktSc3JxV0cxNHE4WUo1ZkF5NTd3X2NnNHZhTTBvOHNsQzhJUlRjWVphLXRlYkx3OHhhNVdjLW9IRzdWSU01ME5JdzdlVWpGOWd4V3BOb1gxVjZIOElaMVE?oc=5", "source_name": "Market source", "published_at": "2026-07-12T20:57:46+00:00", "published_display": "12 Jul 2026 20:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Leadership Hire And Benchmark Additions Change The Bull Case For Kymera Therapeutics (KYMR)?", "summary": "Kymera Therapeutics has appointed Elizabeth Laws as SVP and KT-621 Development Program Leader and been added to Russell value and small-cap benchmarks, which are significant operational and market-profile milestones. These developments, particularly Laws' experience with immunolo", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/does-leadership-hire-and-benchmark-additions-change-the-bull", "source_name": "Simply Wall Street", "published_at": "2026-07-10T16:46:38", "published_display": "10 Jul 2026 16:46", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Kymera (KYMR) the Best Performing American Stock in June 2026?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/kymera-kymr-best-performing-american-104037406.html", "source_name": "Insider Monkey", "published_at": "2026-07-09T10:40:37+00:00", "published_display": "09 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics CEO Mainolfi sells $5.95m in stock", "summary": "Nello Mainolfi, CEO of Kymera Therapeutics, sold $5.95 million worth of company stock after exercising options. The transaction involved 50,000 shares at $119.00 each, occurring when KYMR shares were near their 52-week high after a significant 175% return. This comes as the compa", "url": "https://www.investing.com/news/insider-trading-news/kymera-therapeutics-ceo-mainolfi-sells-595m-in-stock-93CH-4780593", "source_name": "Investing.com", "published_at": "2026-07-08T17:42:18", "published_display": "08 Jul 2026 17:42", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics(KYMR.US) Officer Sells US$5.95 Million in Common Stock", "summary": "A Kymera Therapeutics (KYMR.US) officer sold a significant amount of common stock, totaling US$5.95 million. This transaction indicates insider selling activity at the company.", "url": "https://www.moomoo.com/news/post/72609560/kymera-therapeutics-kymrus-officer-sells-us-5-95-million-in", "source_name": "Moomoo", "published_at": "2026-07-08T17:42:18", "published_display": "08 Jul 2026 17:42", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics Insider Sold Shares Worth $5,950,000, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/kymera-therapeutics-insider-sold-shares-073158288.html", "source_name": "MT Newswires", "published_at": "2026-07-08T07:31:58+00:00", "published_display": "08 Jul 2026 07:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Kymera Therapeutics Inc For: 7 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Kymera Therapeutics Inc, dated July 7th. It indicates a stock performance of -3.10% for KYMR. The article primarily serves as a placeholder for the Form 4 information, surrounded by general market data and news headli", "url": "https://ng.investing.com/news/stock-market-news/form-4-kymera-therapeutics-inc-for-7-july-93CH-2590124", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T00:39:36", "published_display": "08 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics CEO Mainolfi sells $5.95m in stock By Investing.com", "summary": "Kymera Therapeutics, Inc. CEO Nello Mainolfi sold 50,000 shares of common stock worth $5.95 million after exercising stock options. This transaction was executed under a Rule 10b5-1 trading plan. The sale followed significant company advancements, including accelerated enrollment", "url": "https://m.za.investing.com/news/stock-market-news/kymera-therapeutics-ceo-mainolfi-sells-595m-in-stock-93CH-4359585?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-08T00:10:48", "published_display": "08 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) Following Faster KT 621 Trial Progress Still Looks Modestly Undervalued", "summary": "Kymera Therapeutics (KYMR) has completed patient enrollment for its KT-621 trial ahead of schedule, accelerating the timeline for topline data. Despite recent strong share price performance and index inclusion, analysts suggest the stock is still modestly undervalued, with a cons", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/kymera-therapeutics-kymr-following-faster-kt-621-trial-progr", "source_name": "Simply Wall Street", "published_at": "2026-07-07T11:10:48", "published_display": "07 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader", "summary": "Kymera Therapeutics has appointed Elizabeth Laws, Ph.D., as Senior Vice President, KT-621 Development Program Leader. Dr. Laws, formerly an immunology leader at Sanofi, will lead the global development strategy for KT-621, a first-in-class oral STAT6 degrader for immunological di", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/GlobeNewswire/3158526/kymera-therapeutics-appoints-elizabeth-laws-ph-d-as-senior-vice-president-global-program-team-leader-for-kt-621-first-in-class-oral-stat6-degrader/", "source_name": "The Globe and Mail", "published_at": "2026-07-07T11:10:47", "published_display": "07 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics Insider Sold Shares Worth $8,864,829, According to a Recent SEC Filing", "summary": "A recent SEC filing revealed that an insider at Kymera Therapeutics sold shares valued at $8,864,829. This transaction provides insight into insider activity at the company.", "url": "https://www.moomoo.com/news/post/72506052/kymera-therapeutics-insider-sold-shares-worth-8864829-according-to-a?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T05:10:48", "published_display": "07 Jul 2026 05:10", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics Insider Sold Shares Worth $9,223,527, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/kymera-therapeutics-insider-sold-shares-081145747.html", "source_name": "MT Newswires", "published_at": "2026-07-06T08:11:45+00:00", "published_display": "06 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYMR - Kymera Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of Kymera Therapeutics Inc (KYMR), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider/institutional o", "url": "https://finviz.com/stock?t=KYMR&ta=1&p=d&ty=oc&r=m3&ov=list_strike&s=55", "source_name": "Finviz", "published_at": "2026-07-04T16:10:19", "published_display": "04 Jul 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYMR - Kymera Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial snapshot of Kymera Therapeutics Inc (KYMR), listing key metrics such as market capitalization, sales, earnings per share, and various financial ratios. It also includes information on volatility, share performance over different periods,", "url": "https://finviz.com/stock?t=KYMR&ta=1&p=d&ty=ocv&b=2&e=2026-07-17", "source_name": "Finviz", "published_at": "2026-07-03T13:39:11", "published_display": "03 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) Is Up 16.7% After KT-621 Trial Acceleration And Index Additions Has The Bull Case Changed?", "summary": "Kymera Therapeutics (KYMR) has seen a 16.7% stock increase following the early completion of enrollment for its KT-621 Phase 2b trial, updated timelines for data and Phase 3 initiation, new Board Chairman Felix J. Baker, and inclusion in Russell indices. These developments accele", "url": "https://www.sahmcapital.com/news/content/kymera-therapeutics-kymr-is-up-167-after-kt-621-trial-acceleration-and-index-additions-has-the-bull-case-changed-2026-07-01", "source_name": "Sahm", "published_at": "2026-07-03T04:40:36", "published_display": "03 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) Stock Looks Fully Priced After A 405% Run", "summary": "Kymera Therapeutics (KYMR) stock has seen a 405% return over three years but appears expensive based on Simply Wall St\u2019s valuation checks, scoring 1 out of 6. The article questions whether the recent surge and high valuation leave enough room for investors, given the remaining ri", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/kymera-therapeutics-kymr-stock-looks-fully-priced-after-a-40", "source_name": "Simply Wall Street", "published_at": "2026-07-03T04:10:30", "published_display": "03 Jul 2026 04:10", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics(KYMR.US) Officer Sells US$9.22 Million in Common Stock", "summary": "A Kymera Therapeutics (KYMR.US) officer recently sold common stock valued at $9.22 million. This significant insider transaction could be noted by investors monitoring company leadership's actions.", "url": "https://www.moomoo.com/news/post/72420282/kymera-therapeutics-kymrus-officer-sells-us-9-22-million-in", "source_name": "Moomoo", "published_at": "2026-07-03T01:10:30", "published_display": "03 Jul 2026 01:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Noah Goodman Sells Shares of Kymera Therapeutics Inc (KYMR)", "summary": "Noah Goodman, Chief Business Officer at Kymera Therapeutics Inc, sold 3,389 shares of the company on July 1, 2026. This sale follows a pattern of 45 insider sells against only 1 insider buy over the past year. The stock is currently trading at $114.29, which is significantly over", "url": "https://www.gurufocus.com/news/8943940/insider-sell-noah-goodman-sells-shares-of-kymera-therapeutics-inc-kymr", "source_name": "GuruFocus", "published_at": "2026-07-03T00:09:38", "published_display": "03 Jul 2026 00:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(SEC Amendment) Kymera Therapeutics(KYMR.US) Director Sells US$8.28 Million in Common Stock", "summary": "A director at Kymera Therapeutics (KYMR.US) sold common stock valued at US$8.28 million. This information was disclosed in an SEC Amendment filing.", "url": "https://www.moomoo.com/news/post/72419479/sec-amendment-kymera-therapeutics-kymrus-director-sells-us-8-28", "source_name": "Moomoo", "published_at": "2026-07-02T22:09:39", "published_display": "02 Jul 2026 22:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug", "summary": "Kymera Therapeutics (KYMR) stock has risen 50.9% year-to-date due to strong investor optimism surrounding its lead drug candidate, KT-621, for atopic dermatitis and asthma. The company recently completed enrollment for its phase IIb BROADEN2 study ahead of schedule, with pivotal ", "url": "https://finance.yahoo.com/healthcare/articles/kymr-stock-soars-51-ytd-170600007.html", "source_name": "Market source", "published_at": "2026-07-02T15:40:02", "published_display": "02 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Kymera Therapeutics For: 2 July By Investing.com", "summary": "This article announces the filing of Form 144 for Kymera Therapeutics (KYMR) on July 2nd, without providing further details on the content of the filing. It is presented within a news aggregator format by Investing.com, surrounded by various market data and other news headlines. ", "url": "https://ca.investing.com/news/stock-market-news/form-144-kymera-therapeutics-for-2-july-93CH-4718312", "source_name": "Investing.com Canada", "published_at": "2026-07-02T12:40:52", "published_display": "02 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) Stock Gets Fair Value Bump After KT 621 Timeline Shift", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPV1hWRnp3bkY1ZEhreGhYSWFBR2FVcHlNY3RCRFUyR1RlNXR0UVZSNW5OcWxKblYtUjQ5YndhZ2tuZmxqaXBidFN4WmtyaF94NTVZQWVSSS1WLWFvTTJsc0c2a2VvWXRuMWFkNnRsS0N4aWZaeEFCSFlVc3hFQlRJRkNfZ0c3LU92ZGJlQ0E1RW9DU0tvVWQ5Sm1rUl9HZk14YVE?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Accelerated KT-621 Trial, Index Additions, and New Chair Will Impact Kymera Therapeutics (KYMR) Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNdGlDbk9uOTBvZ3hMaWxjSzBSVEpIZFkwSWMteThJbGkwVmtGbWdfOW1XVE9samc4NG1nYVVYNkd2NFN0OVNLYkdoNDhQa00tUEdIWlljZmJBaFowYTNvaUFQdy1URDZBNnpLR1p3VVZYLVlGaUE3MzFjMkVRWEZIN3pLRW1FdGxZam9JaWdxRTBsQnFkT3c?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics(KYMR.US) Director Sells US$59.88 Million in Common Stock", "summary": "A director at Kymera Therapeutics (KYMR.US) has recently sold common stock valued at US$59.88 million. This significant insider transaction indicates a major change in the director's holdings in the company. Further details regarding the transaction would be available in the offi", "url": "https://www.moomoo.com/news/post/72287802/kymera-therapeutics-kymrus-director-sells-us-59-88-million-in", "source_name": "Moomoo", "published_at": "2026-07-01T14:40:52", "published_display": "01 Jul 2026 14:40", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Kymera Therapeutics Inc For: 30 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNWEF4eE5NbDFSc3hCcTFlOEoxQk05bjhNVWxqdmpTSVByQzR3ZmgwcGNDTlVFVmdxR1M0YTNVUkV4eWlBT1lrNXRQR254bnpBNURXa2liRldEVUJSeXdRZlpCTXBxUGE3V25sSngtQ0t4cGp2UmFuNEVxNjU5QkJkX2NucFFkS3hLOEZ2MmFVcTRNZnNxTV9FbkRNTzk3MkVDWnBSdmZB?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-30T21:40:21+00:00", "published_display": "30 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 | Kymera Therapeutics(KYMR.US) Insider Proposes to Sell 6.69 Million in Common Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPdGdKN1ZLcHZDSlFZd2xoSTFhdTlmRW5iT3owVmIyUi1lWEcyX3RfaWNVa3M0dGFJNWowYW13cWttdkduS0lsejl4Mlo3eEFZaXFLc25ERWR6ZjB3cHNPR3QwTDVXT0JOVEZVLWFjWUlYWUJ0eVhSQ1lDaVI3emNrMHJiV3R4a1RaSU1SSVp4S09YVWVVTXY1ZzUwNHlZYXVrVjRBZHowUXA?oc=5", "source_name": "Moomoo", "published_at": "2026-06-26T20:52:32+00:00", "published_display": "26 Jun 2026 20:52", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Kymera Therapeutics Inc For: 26 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOUFBsR0RqdkNYUVFnSldmeERObVBvbHJOdG0xTTdGNHZKa0JkdFZyUmJWS1VMVzRoeHVyaHBTRGJUOFV2SUZVanRNTVU5aEw0RTl5VTJSNU1ZWUhxV09pNm9RNmJWTkNlUjdTaE0xWjQ1WGdRVmZYWUgxeXcwaFJ0bW9WMzlsdmpDeW9XbEVZSVdXVEZhTmFsUDBwSVRDVENUTEEzX1V3?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Kymera Therapeutics Stock Popped This Week", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOZ0xrTVd0cFRpY2NpR3F6dnNXb05USlFYUk5lS3JRNGFZN2pnMC1mMWtQaFAwYjF0elYyQWNLUFh0NGN4YmZ6Zy1TSzBZVjJmSGpaRGN1YlBPb3lEZnVZVEM4NXc2QUlOUE9NOHdEdnpCdVJrcm5TMkNtaktsRnlEYU4tbGZQS2tSQTJsUS1OSENaWGM?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPNVJSUFYwNjhObF9wMVE4dzBrWHZDWnVGUGI5WDJxMC0zZVl2NU1uYy1PUE1XVDhMb3d5dmJWS1lVVnVIU3E4eWNfWjdjRkUtNHpMMGg2a09XVEs3Z0tVVzVDckR3SjVaTlgzUXNlMUhqQUp2VExyOFdQd3RvZURFNTFKZlFNM3kwRjJEUjJWUUdCU0VNTGZmWTZncWhHaVRfODNvTWRR?oc=5", "source_name": "Market source", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics KYMR Stock Surges On Sanofi Milestone", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOSXBZb1VVUmNDWGxYTnUzdlBJek10Q2ZPdGc0MjRoVUV5Vkg0Tm9YQjJ3YXozNjlVYVo4OEN6RkhJdnYtZUJWV0lfZVNBUHRYYmptdlhTMEtGNHB4TFJsakpYbEVGVW4zb1ZVbVlSM25iNlpsZVpxemcxVkVxaHNSQm5jVQ?oc=5", "source_name": "timothysykes.com", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics KYMR Jumps As Degrader Pipeline Advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOR1F0eFh6S2FfSHZjNDRsVm9UM2VvM2l3N0Y5XzhXTDNCa3NIdVJrQ0F3VVFkYTBQdWlDMktsQUI4UExhVlllYXVDYU80Q05TcjUyNTJGNXhVVXE5QmNUakJDTHJjbGlnNkVTbE1Ec3lnMUpaUEN3ZHNMbnY3bWlxZXJsaTQ?oc=5", "source_name": "StocksToTrade", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics KYMR Stock Jumps On Pipeline Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOUXdZcWdwQmxIanJNZUhUTXAyMkpRdXNlbXdsdHFJdk90SDJMdlNYUFNzdTE0dUNKdkZLNl83VnJoN2swWFRmNS01dXg0Rk5PTmZhbnNYeEFsSkdtZ09ZMDBTSTJaT0NUelNrRkdNN2REWl85MEozRUNRNXJhZXlJdkZnQmNNQlBU?oc=5", "source_name": "timothysykes.com", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) Soars As Pipeline And Partnerships Advance", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPYk5Db290ZWwzb3NhdkR6ZTliUUxCZjd2bWlPX1ZhSzNLRWNyU1hBQ1ZvajNvai1WMXBjdWJkRWRxaHRRemxKbEpiX1UyQmJrRnhIY1k5VlE4LV9xMU9IUktaM1ZYWUFPbHlsS0wwN1V1aTZ3a0V6ZjZxdVFoSHNKcQ?oc=5", "source_name": "timothysykes.com", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera stock climbs on expedited eczema study (KYMR:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPUVZrV2MwZXIzbVBSbHFTTHh5MnQwY2JRRVYwY2YwTkZUUGxlNWF2NkZsMlBmS3lPS3lGOThRWWpjYlZFdENPNEJpOF9IYklISjhFR09uWC1aa2xpSUZ5OXBwdk1mWkZUMzVPeHNEcXRvOHdfM085T3pleFU1UEdIOHJCS1paaWM?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOZEZCS1ppUktfdFdFb1JQWDYxdkcwcnU4TTBFY1lYbklPWmlSNFpzRUxLaExGZW51OGhmRTgzcElFTW9iRWg3UFRkZ0dhVTI1S0JVWkpZbjdsOEtNbjhPNmdRLVJUSlNteFd5a040M2F5ZTVlUUthTFAtcUNfRnhEeDNxVENYN29FM2xZUDBxNmdpWXJqWHZJVklYZEFkVWc?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Kymera Therapeutics Inc For: 22 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPckZlVTExeDFRamY2MU9EMXR2Q0RNbGl2YWcwYWtYeVVmUGctSTg3akVlUzdkSXZ1a0pjdU1OZy0xXzVmaVkwYW9JZnhROTNnQUFkeUF2VVNmWkJKakRzcDdMTVN5aGY5dlZLWGhjZWZxaUJCaGthaU9hV3hDeDF5a1pFUlRlMEgyajlob05vQmtMUTNxN0d2TVJ1UFlRSlg5UEY1VXFB?oc=5", "source_name": "Investing.com India", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics Stock (KYMR) Opinions on Director's Substantial Share Sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNekJmTm5SYm1adHUxaTdreTNtY3Z1NmlwLXRabkVWXzZQOTE5VXdBOVlUNzY4TWVNVmhqcHpiOUR3bDlua0RXSW5Cc2hVTXgtNkVHVjNvbXRCeWg0UEwwT25vaXlFeFV2cEN5UUZ5R3RJTlMtVGRFdy1uVEJSNHV1MW1CTVhHbjF0dDNVTnl6RGFUUFhlTmdlWjJLUUJjSi1TcjRHUVpsMWpndWxTZGxEczk3OVdJUkl5?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Kymera Therapeutics stock surging today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxONkxIT2M4R0ROd29BT2doLVk1dTFHT3doX2VRNm01NzR6WUJHYzYxRm1GRVEyT21EYnhIV2poTkViQ196ZHhXckV1VS1uT1IyemtVeWdQWjJUTFJCZGdYV1l6LVNxcVYxMVpybmlLZXZBR3lTdDhvV2g3MDZzZF85eTJqTC1XUTlzYTdQTDZud1BPa0R5RjRod0R6RnFNc2FwdXpWOHVLemYwMWlL?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Kymera Therapeutics (KYMR) Valuation After Recent Share Price Rebound", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPZHJ1NjlCSDVfdl9vTGp0b2xoTGVXY19CcmVHNDRkd3JTdU1hYnpqSGhwSHF6N0Q4MFhETVA3QnpETWp4VW1YTnRCRThabi0tM0NqS3BYSm8wVzFfR1VZbHdJZVBTQUZhaXJjQkViYkRzcnI4S1VEczd0dU16aEZmNEVDS1VrSllsR25tR2FHN1VxdW80VHFRb2EwRmxTQTRRUnJKLTA0dXpYT291eEE?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Kymera Therapeutics (KYMR) Investment Narrative Is Evolving Without New Analyst Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQR3hzVTZWLXhRYy1vcWJZanYzVFJSMmN2VW5fRTV4QTBqSXc5clFvWU9aekpmNGMtajRFXzBISXVGZWpodE95a2FEQWk2cERlZDIySE9ubktFMTRoZjN1VVNLSkZmRHg4a21VanVxYmlBR1MwQVdZQjhjVnBYQlQ5X0tYWmNpMGdxeG5jZzUtX0JoRFFnOGlPUTlsdW1UdF9udkVpeXVITVZsc3FXT1RJ?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) Valuation Check After New KT-621 And KT-579 Clinical And Preclinical Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPNEJ1UmZDT2R1X0JMTk54cVFJN1o0Zml5SmFDN1FVUkw5eEtJeXkwdklmQmNBS0thV3VRV1RrMmp4RnVrYkRSZGdUZVNWM0VUVW5hUHl6M01oUG03WUxmSkJ4eW9ESlRVVEg5U3hCN2xaTWx6a0xqaURxZHZRWGV6d0pVOHktMjBKOFdiR0ZIcGdLSVhLbWdQVWVNdzdnSGdKRTdYemJVMDBPLTBvNHc?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Kymera Therapeutics (KYMR) Story Is Shifting Around KT-621 And Degrader Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPZDdVRmJ3T1YtcV9lZTFZSnFlYUI5VUxFbXhBSVNOOHJuMTJocHNacldhZllRZzJQa3dTUldHSnlRYkpVSkh6NWJfa2dqOVNVaVQ3WmU4b1JGSVBId3MwMlJ0Rk1FSk5KYkJCYmdUZFZGSm1YMllYS2prS2RmdDlSWnM5MjR5SHhuOHJIWWJKdnI1NVZUYXM1bksxOWp5MHJmcWUtVk93S29jcTdL?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kymera Therapeutics (KYMR) Q1 2026 Deepening Losses Test Bullish Revenue Growth Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 103, "total_relevant": 64, "sentiment_summary": {"positive": 15, "negative": 14, "neutral": 35, "score": 50, "total": 64, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 86, "events": [{"event": "general", "label": "Market update", "weight": 25.1, "count": 45}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 11}, {"event": "analyst", "label": "Analyst action", "weight": 3.85, "count": 7}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 14}, "market_context": {"has_market_context": true, "latest_close": 119.35, "latest_week": "2026-07-10", "one_week_move": 5.1, "four_week_move": 38.4, "twelve_week_move": 36.1, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.064077, "market_dynamics_buy_signal": false, "relative_strength": 44.02847, "fair_value_gap": 155.9, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 53.7643, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+5.1% over one week, +38.4% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "Moomoo", "count": 7}, {"label": "MT Newswires", "count": 4}, {"label": "Quartr", "count": 3}, {"label": "Simply Wall Street", "count": 3}, {"label": "Investing.com Canada", "count": 3}, {"label": "timothysykes.com", "count": 3}, {"label": "simplywall.st", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 45}, {"label": "Earnings", "count": 11}, {"label": "Analyst action", "count": 7}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "86/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+5.1% over one week, +38.4% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140"}], "updated_at": "2026-07-18T07:07:37.855315+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}